Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 18
2022 138
2023 35
2024 12
2025 12
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation.
Xu S, Jia P, Fang Y, Jin J, Sun Z, Zhou W, Li J, Zhang Y, Wang X, Ren T, Zou Z, Ding X. Xu S, et al. Kidney Int. 2022 May;101(5):987-1002. doi: 10.1016/j.kint.2022.01.029. Epub 2022 Feb 26. Kidney Int. 2022. PMID: 35227690 Free article.
Acute kidney injury (AKI) is a life-threatening condition that is one of most common side effects of cisplatin therapy. ...In vivo studies have shown that pharmacological activation of PPARgamma can prevent cisplatin-induced lipid accumulation, kidney tubule injury …
Acute kidney injury (AKI) is a life-threatening condition that is one of most common side effects of cisplatin therapy. ...In vivo st …
Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathy.
Drovandi S, Lipska-Ziętkiewicz BS, Ozaltin F, Emma F, Gulhan B, Boyer O, Trautmann A, Ziętkiewicz S, Xu H, Shen Q, Rao J, Riedhammer KM, Heemann U, Hoefele J, Stenton SL, Tsygin AN, Ng KH, Fomina S, Benetti E, Aurelle M, Prikhodina L, Schijvens AM, Tabatabaeifar M, Jankowski M, Baiko S, Mao J, Feng C, Deng F, Rousset-Rouviere C, Stańczyk M, Bałasz-Chmielewska I, Fila M, Durkan AM, Levart TK, Dursun I, Esfandiar N, Haas D, Bjerre A, Anarat A, Benz MR, Talebi S, Hooman N, Ariceta G; PodoNet Consortium; mitoNET Consortium; CCGKDD Consortium; Schaefer F. Drovandi S, et al. Kidney Int. 2022 Sep;102(3):592-603. doi: 10.1016/j.kint.2022.02.040. Epub 2022 Apr 26. Kidney Int. 2022. PMID: 35483523 Free article.
None of the patients with COQ8B variants, but 50% of patients with COQ2 and COQ6 variants progressed to kidney failure by age five. At adult age, kidney survival was equally poor (20-25%) across all disorders. A number of sequence variants, including putative local …
None of the patients with COQ8B variants, but 50% of patients with COQ2 and COQ6 variants progressed to kidney failure by age five. A …
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
To verify these findings, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon (16 mg/d) versus placebo in adult patients with primary IgAN at risk of progressing to kidney failure (ClinicalTrials.gov: NCT03643965). NefIgArd wa …
To verify these findings, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon (16 mg/d) versu …
Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/beta-catenin signaling.
Chen X, Tan H, Xu J, Tian Y, Yuan Q, Zuo Y, Chen Q, Hong X, Fu H, Hou FF, Zhou L, Liu Y. Chen X, et al. Kidney Int. 2022 Sep;102(3):506-520. doi: 10.1016/j.kint.2022.04.028. Epub 2022 May 27. Kidney Int. 2022. PMID: 35644285
Diabetic kidney disease (DKD) is one of the most common and devastating complications of diabetic mellitus, and its prevalence is rising worldwide. Klotho, an anti-aging protein, is kidney protective in DKD. However, its large size, prohibitive cost and structural c …
Diabetic kidney disease (DKD) is one of the most common and devastating complications of diabetic mellitus, and its prevalence is ris …
The effectiveness of dressings and securement devices to prevent central venous catheter-associated complications: A systematic review and meta-analysis.
Xu H, Hyun A, Mihala G, Rickard CM, Cooke ML, Lin F, Mitchell M, Ullman AJ. Xu H, et al. Int J Nurs Stud. 2024 Jan;149:104620. doi: 10.1016/j.ijnurstu.2023.104620. Epub 2023 Oct 9. Int J Nurs Stud. 2024. PMID: 37879273 Free article.
METHODS: Following standard Cochrane methods, a systematic search of Cochrane Wounds Trials Register, Cochrane Central Register of Controlled Trials, MEDLINE Ovid, Embase Ovid, EBSCO CINAHL, and multiple clinical trial registries was completed in November 2022. Randomised …
METHODS: Following standard Cochrane methods, a systematic search of Cochrane Wounds Trials Register, Cochrane Central Register of Controlle …
The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.
Zhou W, Yang X, Jin J, Cheng M, Li Y, Bai Y, Xu J. Zhou W, et al. Int Urol Nephrol. 2024 Jan;56(1):181-190. doi: 10.1007/s11255-023-03599-w. Epub 2023 May 17. Int Urol Nephrol. 2024. PMID: 37195574
BACKGROUND: Sacubitril/valsartan, a new pharmacological class of angiotensin receptor neprilysin inhibitor, is beneficial to heart failure through blocking the degradation of natriuretic peptides and inhibiting renin-angiotensin-aldosterone system (RAAS) activation which also rel …
BACKGROUND: Sacubitril/valsartan, a new pharmacological class of angiotensin receptor neprilysin inhibitor, is beneficial to heart failure t …
Corrigendum to Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, Chan J, Thalakola A, Le T, Xu L, Wang L, Jiang K, Wang X, Wang H, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R. "Role of the macula densa sodium glucose cotransporter type 1-neuronal nitric oxide synthase-tubuloglomerular feedback pathway in diabetic hyperfiltration." Kidney Int. 2022;101:541-550.
Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, Chan J, Thalakola A, Le T, Xu L, Wang L, Jiang K, Wang X, Wang H, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R. Zhang J, et al. Kidney Int. 2022 Aug;102(2):448. doi: 10.1016/j.kint.2022.05.011. Kidney Int. 2022. PMID: 35870819 Free PMC article. No abstract available.
DKS26 Alleviates Ischemia-Reperfusion Injury-Induced Acute Kidney Injury by Stabilizing Vitamin D Receptors to Inhibit the Inflammatory Pathway of NF-kappaB P65.
Liang L, Ruan Y, Yu X, Tan W, Xu X, Jia J, Peng J, Wang F, Peng Y, Chen Y, Liu L, Guo B, Zhang J, Wang Y. Liang L, et al. Int J Mol Sci. 2025 Mar 25;26(7):2985. doi: 10.3390/ijms26072985. Int J Mol Sci. 2025. PMID: 40243616 Free PMC article.
Acute kidney injury (AKI) is a common critical clinical disease with high morbidity and mortality rates. ...
Acute kidney injury (AKI) is a common critical clinical disease with high morbidity and mortality rates. ...
Circulating irisin level in chronic kidney disease patients: a systematic review and meta-analysis.
Gan W, Chen W, Li T, Shao D, Xu F, Huo S, Li C, Yang Z, Zeng X. Gan W, et al. Int Urol Nephrol. 2022 Jun;54(6):1295-1302. doi: 10.1007/s11255-021-03000-8. Epub 2021 Sep 28. Int Urol Nephrol. 2022. PMID: 34585311
However, the association between irisin and chronic kidney disease (CKD) is unclear. This systematic review aimed to assess circulating irisin levels in patients with CKD and compare them with those in non-CKD patients. ...
However, the association between irisin and chronic kidney disease (CKD) is unclear. This systematic review aimed to assess circulati …
168 results